## CITATION REPORT List of articles citing

A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine

DOI: 10.1136/ard.48.5.389 Annals of the Rheumatic Diseases, 1989, 48, 389-95.

Source: https://exaly.com/paper-pdf/20347040/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper   | IF            | Citations |
|----|---|---------------|-----------|
| 52 | Phospholipase A2 and inflammation. <i>Annals of the Rheumatic Diseases</i> , <b>1989</b> , 48, 962-3  | 2.4           | 4         |
| 51 | Disease assessment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>1989</b> , 48, 962   | 2.4           | 2         |
| 50 | Antimalarials in rheumatic diseases. <i>Bailliereys Clinical Rheumatology</i> , <b>1990</b> , 4, 467-89   |               | 46        |
| 49 | The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. <i>Arthritis and Rheumatism</i> , <b>1990</b> , 33, 1449-61                                |               | 397       |
| 48 | Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine. <i>Scandinavian Journal of Rheumatology</i> , <b>1990</b> , 19, 407-12                   | 1.9           | 43        |
| 47 | Hemolysis during low-dose sulfasalazine treatment in rheumatoid arthritis patients. <i>Scandinavian Journal of Rheumatology</i> , <b>1991</b> , 20, 52-7  | 1.9           | 4         |
| 46 | Intra-articular steroids: confounder of clinical trials. <i>Clinical Rheumatology</i> , <b>1991</b> , 10, 38-42   | 3.9           | 11        |
| 45 | Rheumatology. <i>Postgraduate Medical Journal</i> , <b>1991</b> , 67, 114-39  | 2             |           |
| 44 | Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>1992</b> , 51, 1318-21                   | 2.4           | 47        |
| 43 | The impact of endpoint measures in rheumatoid arthritis clinical trials. <i>Seminars in Arthritis and Rheumatism</i> , <b>1992</b> , 21, 287-94   | 5.3           | 24        |
| 42 | Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. <i>Arthritis and Rheumatism</i> , <b>1992</b> , 35, 1117-25 |               | 186       |
| 41 | Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. <i>Arthritis and Rheumatism</i> , <b>1993</b> , 36, 1501-9                                      |               | 114       |
| 40 | A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs. <i>International Journal of Clinical Pharmacy</i> , <b>1993</b> , 15, 203-7                              |               | 3         |
| 39 | Rheumatoid arthritis in the aged. Incidence and optimal management. <i>Drugs and Aging</i> , <b>1993</b> , 3, 487-50  | <b>)1</b> 4.7 | 18        |
| 38 | A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>1994</b> , 37, 637-43                 |               | 54        |
| 37 | Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>1995</b> , 54, 256-62                            | 2.4           | 12        |
| 36 | Advances and issues in the pharmacotherapy of rheumatoid arthritis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>1995</b> , 20, 131-47   | 2.2           | 2         |

## (2009-1995)

| 35 | A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>1995</b> , 14, 531-6  | 3.9           | 7    |
|----|--|---------------|------|
| 34 | Category III Symptom-Modifying Antirheumatic Drugs. <i>BioDrugs</i> , <b>1995</b> , 3, 196-217   |               | 6    |
| 33 | Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. <i>Drugs</i> , <b>1995</b> , 50, 137-56   | 12.1          | 71   |
| 32 | Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. <i>Arthritis and</i> |               | 1258 |
| 31 | Reconnation, 1996, 33, 34,46  Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs).  Bailliereys Clinical Rheumatology, 1997, 11, 65-82   |               | 16   |
| 30 | Sulphasalazine in the treatment of children with chronic arthritis. <i>Clinical Rheumatology</i> , <b>1998</b> , 17, 359-6   | 5 <b>3</b> .9 | 27   |
| 29 | Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. <i>Annals of the Rheumatic Diseases</i> , <b>2000</b> , 59, 468-77   | 2.4           | 47   |
| 28 | Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. <i>American Journal of Therapeutics</i> , <b>2001</b> , 8, 123-43   | 1             | 36   |
| 27 | Methotrexate versus chloroquine in the treatment of rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , <b>2003</b> , 6, 26-31  |               | 1    |
| 26 | Sulfasalazine. <b>2005</b> , 93-132  |               |      |
| 25 | Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. <i>Clinics in Geriatric Medicine</i> , <b>2005</b> , 21, 649-69, viii  | 3.8           | 9    |
| 24 | The evidence for early intervention. <i>Rheumatic Disease Clinics of North America</i> , <b>2005</b> , 31, 575-89  | 2.4           | 20   |
| 23 | Sulfasalazine: a review of its use in the management of rheumatoid arthritis. <i>Drugs</i> , <b>2005</b> , 65, 1825-49   | 12.1          | 121  |
| 22 | Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. <i>Rheumatic Disease Clinics of North America</i> , <b>2007</b> , 33, 197-217  | 2.4           | 32   |
| 21 | American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 762-  | 84            | 1118 |
| 20 | Susceptibility of the Spanish Population to Adverse Effects by Sulfasalazine: Systematic Review. <i>Reumatologā Clūica (English Edition)</i> , <b>2008</b> , 4, 132-135  | 0.1           |      |
| 19 | [Susceptibility of the spanish population to adverse effects by sulfasalazine: systematic review]. <i>Reumatolog a Claica</i> , <b>2008</b> , 4, 132-5   | 0.9           |      |
| 18 | What have we learnt about the development and progression of early RA from RCTs?. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 13-24   | 5.3           | 5    |

| 17 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. <i>Drugs and Aging</i> , <b>2009</b> , 26, 273-93   | 4.7 | 19 |
|----|---|-----|----|
| 16 | Multifaceted effects of hydroxychloroquine in human disease. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 43, 264-72   | 5.3 | 88 |
| 15 | Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 1142-1165 | 2.3 | 5  |
| 14 | 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 357-375  | 2.3 | 60 |
| 13 | Clinical and Structural Efficacy of Hydroxychloroquine in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 36-40   | 4.7 | 16 |
| 12 | Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. <i>Molecules</i> , <b>2020</b> , 25,  | 4.8 | 2  |
| 11 | Hydroxychloroquine for Primary Progressive Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 90, 940-948   | 9.4 | 5  |
| 10 | Rheumatoid Arthritis. <b>1993,</b> 151-167  |     | 1  |
| 9  | A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. <i>Modern Rheumatology</i> , <b>2009</b> , 19, 384-9  | 3.3 | 4  |
| 8  | Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate. <i>Modern Rheumatology</i> , <b>2012</b> , 22, 100-8   | 3.3 | 2  |
| 7  | MEDICAL ASPECTS OF RHEUMATOID ARTHRITIS. Hand Clinics, 1996, 12, 463-475  | 1.7 | 6  |
| 6  | Disease-Modifying Antirheumatic Drug Use in Older Rheumatoid Arthritis Patients. <b>2011</b> , 151-172  |     |    |
| 5  | Arthritis: the therapeutic challenge. Medical Journal of Australia, 1992, 157, 728-9  | 4   | 1  |
| 4  | EFFICACY OF COMBINATION THERAPY OF METHOTREXATE WITH HYDROXYCHLOROQUINE OR SULFASALAZINE IN RHEUMATOID ARTHRITIS PATIENTS IN KUMAON REGION: A COMPARATIVE STUDY. <i>Journal of Evolution of Medical and Dental Sciences</i> , <b>2016</b> , 5, 3303-3307  | 0.1 | 1  |
| 3  | Rheumatoid arthritis. <i>Clinical Evidence</i> , <b>2007</b> , 2007,  |     | 1  |
| 2  | Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: a real-world study <b>2022</b> ,   |     | O  |
| 1  | Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.  |     | 0  |